Allergan PLC (AGN)

236.21
7.10 2.90
NYSE : Health Care
Prev Close 243.27
Open 243.00
Day Low/High 232.05 / 244.27
52 Wk Low/High 195.50 / 322.68
Volume 6.13M
Avg Volume 3.13M
Exchange NYSE
Shares Outstanding 395.95M
Market Cap 100.26B
EPS 10.00
P/E Ratio 20.47
Div & Yield N.A. (N.A)

Latest News

Allergan's Drop Doesn't Shake Our Confidence

Reversal of earlier gains reflects broader pricing-related biotech selloff and potential implications of Apple's EC issues.

David Einhorn Cashed Out of These 9 Stocks

David Einhorn Cashed Out of These 9 Stocks

The going has been a bit tough for David Einhorn lately, and he has been doing some selling in turn.

Pfizer Picks Up AstraZeneca's Antibiotics Business

Pfizer Picks Up AstraZeneca's Antibiotics Business

The deal could be worth $1.5 billion.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

Pfizer buys antibiotics business from AstraZeneca; Tesla unveils Model S version that can go 300 miles on a single charge; U.S. stock futures rise slightly.

9 Stocks Smart Investors Put Their Money in Last Quarter

9 Stocks Smart Investors Put Their Money in Last Quarter

Hedge fund managers continue to flee stocks in the second quarter, but the smart money eyed several potential opportunities, including Charter Communications and Morgan Stanley.

Weekly Roundup

As earnings wind down, focus is drawn to the Fed and oil. The portfolio adds a new name.

TGIEF: It's Expiration Friday

Reviewing which of our positions will be affected.

Allergan (AGN) Stock Should Outperform, Analyst Tells CNBC

Allergan (AGN) Stock Should Outperform, Analyst Tells CNBC

Aureus Asset Management co-founder Karen Firestone told CNBC that Allergan (AGN) stock is poised to see growth in its aesthetics and eye-care services.

Allergan (AGN) Stock Rises, Mizuho Upgrades to 'Buy'

Allergan (AGN) Stock Rises, Mizuho Upgrades to 'Buy'

Allergan (AGN) stock was trading higher pre-market following an upgrade to 'buy' at Mizuho given potential upside from higher gross margins and quarterly beats.

Analysts' Actions -- Allergan, Hormel, L Brands, U.S. Steel and More

Analysts' Actions -- Allergan, Hormel, L Brands, U.S. Steel and More

Here are Friday's top research calls, including upgrades for Allergan, Hormel and L Brands, and a downgrade for U.S. Steel.

4 Stocks Carl Icahn Is Buying in 2016

4 Stocks Carl Icahn Is Buying in 2016

Here's a closer look at some of the stocks Carl Icahn bought in the most recently reported quarter.

For Value Investors, Arbiter Partners Knows How to Pick 'Em

These managers have great track records and I have made money stealing their ideas.

Will Allergan (AGN) Stock Be Helped as Icahn Makes New Bet on Shares?

Will Allergan (AGN) Stock Be Helped as Icahn Makes New Bet on Shares?

Billionaire investor Carl Icahn bought 3.4 million shares of Allergan (AGN) during the 2016 second quarter.

Allergan Sees Action on 13F Deadline Day

Allergan Sees Action on 13F Deadline Day

Appaloosa adds to its stake in the biopharmaceutical company while Jana Partners exits its position.

Why Allergan is Fine Without Large M&A

Why Allergan is Fine Without Large M&A

The Dublin-based drugmaker has some 65-plus mid-to-late stage assets in its pipeline.

Aegon Completes Share Buyback Program

Aegon Completes Share Buyback Program

Weekly Roundup

The major indices hit new highs this week as stocks maintained their shine. In the portfolio, we exited 2 positions and added a name.

It's Time to Go Short Stocks; Here Are Some Ideas

It's Time to Go Short Stocks; Here Are Some Ideas

Besides Tesla, Twitter and Biogen make good candidates.

Allergan Bought Itself an Exciting Opportunity in ForSight

Allergan Bought Itself an Exciting Opportunity in ForSight

The deal builds on leadership positions in Allergan's core therapeutic areas.

Glaucoma Treatment Maker a $95M

Glaucoma Treatment Maker a $95M "Stepping Stone" for Allergan

The deal for ForSight VISION5 aligns with the bolt-on M&A strategy described by CEO Brent Saunders earlier this week.

Allergan Bought Itself an Exciting Opportunity in ForSight

The deal builds on leadership positions in Allergan's core therapeutic areas.

Allergan Stock Is 'Misunderstood'

Allergan Stock Is 'Misunderstood'

AAP portfolio managers Cramer and Mohr defend the drug company after it tops analysts' bottom-line expectations while missing top-line estimates.

Stocks Retreat From Records as Health Care Slumps

Stocks Retreat From Records as Health Care Slumps

Stocks retreat from record highs on Monday as a selloff in health care overshadows a rally in energy.

Stocks Fall as Health Care Selloff Counters Energy Rally

Stocks Fall as Health Care Selloff Counters Energy Rally

Stocks pull slightly lower on Monday as a selloff in health care squares off against a rally in energy.

These 7 Stocks Are Seeing Big Volume Today -- Here's How to Trade Them Now

These 7 Stocks Are Seeing Big Volume Today -- Here's How to Trade Them Now

Here's a technical look at how to trade some of the most active stocks on the market right now.

Take a Long-Term View On Allergan, This Stock Is a Buy

We are confident in the company’s enviable strategic positioning, strong fundamentals and visibility, all of which appear to be lost on the market.